The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations
| Autor: | Zhengtang Chen, An-Mei Zhang, Wenlei Zhuo, Song Lang, Guanghui Li, Jianguo Sun, Ping Hao, Guangkuo Zhu, Yuzhong Duan, Yongdong Feng, Fanglin Chen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
safety Cancer Research medicine.medical_specialty CD3 efficacy NSCLC Internal medicine EGFR-TKI medicine Clinical endpoint Epidermal growth factor receptor Adverse effect Lung cancer RC254-282 Original Research biology business.industry Thymosin Neoplasms. Tumors. Oncology. Including cancer and carcinogens thymosin medicine.disease respiratory tract diseases active EGFR mutations biology.protein Non small cell business CD8 hormones hormone substitutes and hormone antagonists |
| Zdroj: | Frontiers in Oncology, Vol 11 (2021) Frontiers in Oncology |
| DOI: | 10.3389/fonc.2021.659065/full |
| Popis: | ObjectiveTo explore the efficacy and safety of EGFR-TKI combined with thymosin therapy in advanced non-small cell lung cancer (NSCLC) patients harboring active EGFR mutations.MethodsPatients confirmed as advanced NSCLC with active EGFR mutations were recruited from August 2008 to July 2018 retrospectively. Patients treated with EGFR-TKI were classified as the EGFR-TKI group. And those received EGFR-TKI and thymosin therapy were designated as the EGFR-TKI plus thymosin group. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS), tumor response and adverse effects.ResultsThe median PFS was significantly longer in EGFR-TKI plus thymosin group than that in EGFR-TKI group (14.4 months vs. 9.2 months; HR=0.433, 95% CI 0.322 - 0.582, Pvs. 19.8 months; HR=0.430, 95% CI 0.319 - 0.580, PP=0.918). The disease control rate was 96.9% in EGFR-TKI plus thymosin group and 97.7% in EGFR-TKI group (P=1.000). There were no significant differences in adverse effects between the two groups. The number of CD3+T cells in peripheral blood decreased significantly after treatment including both CD3+CD4+T and CD3+CD8+T subsets in EGFR-TKI group, but not in EGFR-TKI plus thymosin group.ConclusionsCombination of EGFR-TKI and thymosin can significantly prolong the PFS and OS compared with EGFR-TKI monotherapy without more adverse events, which offers a new strategy in clinic. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|